| Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias (NCT01149915) | Threshold Pharmaceuticals | 2010-06-01 |
| Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia (NCT01133743) | University Health Network, Toronto | 2010-05-01 |
| Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab (NCT01123356) | Medical University of South Carolina | 2010-05-01 |
| Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia (NCT01069432) | Dartmouth-Hitchcock Medical Center | 2010-05-01 |
| Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) (NCT01010568) | Georgetown University | 2010-04-01 |
| Genomic Analysis of Patients With Chronic Lymphocytic Leukemia (NCT01346020) | Universitaire Ziekenhuizen KU Leuven | 2010-04-01 |
| Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01076556) | National Cancer Institute (NCI) | 2010-04-01 |
| Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia (NCT01088048) | Gilead Sciences | 2010-03-25 |
| An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study (NCT01090414) | Gilead Sciences | 2010-03-22 |
| Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry (NCT01081015) | Celgene | 2010-03-19 |
| Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01024010) | Mayo Clinic | 2010-03-01 |
| Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia (NCT01109264) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2010-03-01 |
| Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT01066663) | Dana-Farber Cancer Institute | 2010-03-01 |
| Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01002755) | M.D. Anderson Cancer Center | 2010-01-19 |
| Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia (NCT01649791) | Roswell Park Cancer Institute | 2010-01-01 |
| A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax). (NCT01021358) | Abbott | 2010-01-01 |
| Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) (NCT01118234) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2009-12-01 |
| Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age (NCT01011894) | Memorial Sloan Kettering Cancer Center | 2009-11-06 |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy (NCT00990587) | University Health Network, Toronto | 2009-10-01 |
| Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL (NCT00974233) | University of Wisconsin, Madison | 2009-10-01 |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer (NCT00975975) | Indiana University | 2009-09-01 |
| Pilot Study of Unrelated Cord Blood Transplantation (NCT00916045) | King's College Hospital NHS Trust | 2009-09-01 |
| Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy (NCT00963495) | University Health Network, Toronto | 2009-08-01 |
| Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT00873457) | Daphne Friedman | 2009-08-01 |
| Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab (NCT00946023) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2009-07-01 |
| T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL (NCT00709033) | Baylor College of Medicine | 2009-07-01 |
| Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT00918723) | Fred Hutchinson Cancer Center | 2009-06-01 |
| Study of Repeat Intranodal Injections of Ad-ISF35 (NCT00942409) | Januario Castro, M.D. | 2009-06-01 |
| A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia (NCT00949988) | University of California, San Diego | 2009-05-01 |
| Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia (NCT00872976) | Bristol-Myers Squibb | 2009-05-01 |
| Protocol to Obtain Blood Samples for Leukemia Research (NCT00889031) | Dartmouth-Hitchcock Medical Center | 2009-04-01 |
| The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) (NCT00868478) | Kaplan Medical Center | 2009-04-01 |
| Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia (NCT01185262) | MD Anderson International Spain SA | 2009-04-01 |
| High-dose HMG-CoA Inhibitor Simvastatin Relapsed CLL (NCT00828282) | John Haslip | 2009-03-01 |
| A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies (NCT00807677) | Millennium Pharmaceuticals, Inc. | 2009-03-01 |
| CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia (NCT01013441) | University of Pennsylvania | 2009-03-01 |
| Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant (NCT00880815) | M.D. Anderson Cancer Center | 2009-02-17 |
| CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL (NCT00586391) | Baylor College of Medicine | 2009-02-01 |
| Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) (NCT00864942) | Georgetown University | 2009-02-01 |
| A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia (NCT00829647) | Scripps Health | 2009-01-01 |
| Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (NCT00849524) | Januario Castro, M.D. | 2009-01-01 |
| LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia (NCT01098188) | Laboratoire français de Fractionnement et de Biotechnologies | 2008-11-01 |
| Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL) (NCT00800566) | M.D. Anderson Cancer Center | 2008-11-01 |
| FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (NCT00769522) | German CLL Study Group | 2008-10-02 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery (NCT00608361) | National Cancer Institute (NCI) | 2008-10-01 |
| Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) (NCT00854646) | Traws Pharma, Inc. | 2008-10-01 |
| Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease (NCT01051115) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2008-10-01 |
| Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL) (NCT00758693) | University of Kentucky | 2008-10-01 |
| Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia (NCT00836043) | Genzyme, a Sanofi Company | 2008-10-01 |
| Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia (NCT00759603) | M.D. Anderson Cancer Center | 2008-09-01 |
| A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) (NCT00749502) | Tesaro, Inc. | 2008-09-01 |
| Study of Efficacy and Safety of Valproic Acid in Chronic Lymphocytic Leukemia (CLL) (NCT00810680) | All India Institute of Medical Sciences | 2008-09-01 |
| A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL (NCT00772486) | Memgen, LLC | 2008-09-01 |
| Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL) (NCT00759798) | M.D. Anderson Cancer Center | 2008-08-13 |
| Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) (NCT00899353) | Marshall University | 2008-08-01 |
| Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL) (NCT00593944) | Bristol-Myers Squibb | 2008-08-01 |
| Assess the Oral Bioavailability of New ABT-263 Formulations (NCT00743028) | Abbott | 2008-08-01 |
| Alemtuzumab + Rituximab Consolidation in CLL (NCT00771602) | M.D. Anderson Cancer Center | 2008-08-01 |
| Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT00735930) | National Cancer Institute (NCI) | 2008-08-01 |
| Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT (NCT00709592) | Virginia Commonwealth University | 2008-07-21 |
| A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL) (NCT00676871) | MedImmune LLC | 2008-06-01 |
| 8-Chloro-Adenosine in Chronic Lymphocytic Leukemia (NCT00714103) | M.D. Anderson Cancer Center | 2008-06-01 |
| Natural Killer Cells Function in Patients With Chronic Lymphocytic Leukemia (NCT00934986) | Institut Paoli-Calmettes | 2008-03-01 |
| Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy (NCT00727415) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2008-02-01 |
| Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL) (NCT00860457) | Georgetown University | 2008-02-01 |
| Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine (NCT01392079) | University of Ulm | 2008-02-01 |
| Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (NCT00801060) | Biogen | 2008-02-01 |
| Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) (NCT00628238) | Chronic Lymphocytic Leukemia Research Consortium | 2008-02-01 |
| Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia (NCT00792831) | Italfarmaco | 2008-02-01 |
| Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease (NCT00632359) | M.D. Anderson Cancer Center | 2008-02-01 |
| HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia (NCT00524667) | CancerCare Manitoba | 2008-01-01 |
| Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant (NCT00674427) | University of Pennsylvania | 2008-01-01 |
| Investigation of the Cylex® ImmuKnow® Assay (NCT00569842) | Indiana University | 2007-11-01 |
| Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL (NCT00543114) | Dana-Farber Cancer Institute | 2007-10-01 |
| Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients (NCT00596336) | The Royal Bournemouth Hospital | 2007-10-01 |
| Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older (NCT00535873) | M.D. Anderson Cancer Center | 2007-10-01 |
| A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT00496132) | Genentech, Inc. | 2007-08-27 |
| A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT00481091) | AbbVie | 2007-07-25 |
| A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) (NCT00499239) | Gilead Sciences | 2007-07-01 |
| Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies (NCT00504972) | Weill Medical College of Cornell University | 2007-06-01 |
| A Phase I Extension Trial of Repeated Infusions of ISF35 (NCT00783588) | Memgen, LLC | 2007-05-01 |
| Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia. (NCT00466895) | Leslie Andritsos | 2007-04-01 |
| FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL) (NCT00448019) | M.D. Anderson Cancer Center | 2007-02-01 |
| Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies (NCT00446342) | Sunesis Pharmaceuticals | 2007-02-01 |
| Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination (NCT00442130) | Dana-Farber Cancer Institute | 2007-02-01 |
| Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia (NCT00514696) | La Jolla Pharmaceutical Company | 2007-02-01 |
| Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation (NCT01445132) | National Cancer Institute (NCI) | 2007-01-11 |
| Dasatinib in Relapsed Chronic Lymphocytic Leukemia (NCT00438854) | Massachusetts General Hospital | 2006-12-01 |
| Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation (NCT00428233) | Dana-Farber Cancer Institute | 2006-11-01 |
| Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) (NCT00391066) | Biogen | 2006-11-01 |
| FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia (NCT00381004) | M.D. Anderson Cancer Center | 2006-09-01 |
| A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) (NCT00779883) | Memgen, LLC | 2006-06-01 |
| Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL (NCT00330252) | Dana-Farber Cancer Institute | 2006-05-01 |
| Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (NCT00850057) | University of California, San Diego | 2006-02-01 |
| Study of Immune Response Modifier in the Treatment of Hematologic Malignancies (NCT00276159) | Masonic Cancer Center, University of Minnesota | 2006-01-01 |
| Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia (NCT00286780) | Ascenta Therapeutics | 2006-01-01 |
| Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL) (NCT00267059) | M.D. Anderson Cancer Center | 2005-12-01 |
| Characterization of Proliferating Compartment in B-Cell Patients and in Healthy Aging Subjects (NCT01110863) | Northwell Health | 2005-12-01 |
| Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease (NCT00719888) | Fred Hutchinson Cancer Center | 2005-11-18 |
| Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia (NCT00274989) | German CLL Study Group | 2005-11-01 |